EpiVax uses "immunoinformatics" computer modeling, gene sequencing and molecular immunology to develop new vaccines and to improve the immunogenicity profiles of new drugs. Thinking outside the box at EpiVax has often led to paradigm-shifting discoveries. EpiVax won the prestigious AAPS Innovation award for its Tregitope technology. Responsibility is another key attribute: EpiVax counts 6 of the eight largest Biotech companies in the world among its clients. EpiVax is also globally responsible: the company supports a number of not-for-profits that improve human health around the world. The company was founded in 1998 with support from the Slater Biotechnology Fund. In 2002, EpiVax was invited by the FDA to participate in one of the first ever "Immunogenicity" meetings. By 2006, EpiVax had developed a reputation as “thought leaders” in the field of therapeutic proteins and immunogenicity screening, providing fee-for-service solutions for first tier Pharma companies, mid to small biotech companies, and academics. The company has a solid reputation for publishing its work in academic journals (>170 publications, compared to <20 for its competitors). EpiVax’ 22 employees are “an incredibly creative group,” says De Groot, the company’s CEO and CSO. “We try to foster a balance between customer focus, Yankee frugality, and intellectual curiosity,” she says. “The critical components of our company’s innovations process are free thought, unencumbered imagination and an ability to connect the dots.” The EpiVax team also prides itself on delivering on promises. “We maintain a close relationship with our clients,” De Groot says. We aim to treat our clients with respect and provide capable, intelligent solutions for their needs.”
Show more
HQProvidence, US
Size (employees)43 (est)
EpiVax was founded in 1998 and is headquartered in Providence, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

EpiVax Office Locations

EpiVax has an office in Providence
Providence, US (HQ)
146 Clifford St
Show all (1)
Report incorrect company information

EpiVax Financials and Metrics

Summary Metrics

Founding Date


EpiVax total Funding

$3.2 m

EpiVax latest funding size

$55 k

Time since last funding

6 years ago

EpiVax investors

EpiVax's latest funding round in November 2012 was reported to be $55 k. In total, EpiVax has raised $3.2 m
Show all financial metrics
Report incorrect company information

EpiVax Online and Social Media Presence

Embed Graph
Report incorrect company information

EpiVax News and Updates

La Oficina de Medicamentos Genéricos adjudica un contrato de la FDA por valor de un millón de dólares a CUBRC y EpiVax

- La Oficina de Medicamentos Genéricos (OGD/FDA) adjudica un contrato de la FDA por valor de un millón de dólares a CUBRC y EpiVax con miras a la demostración y validación de una serie de métodos de evaluación del riesgo de inmunogenicidad que presentan los péptidos terapéuticos genéricos ...

Office of Generic Drugs (OGD/FDA) vergibt FDA-Vertrag im Wert von 1 Mio. USD an CUBRC und EpiVax für den Nachweis und die Validierung von Verfahren zur Risikobewertung der Immunogenität für generische Peptidpräparate und deren Verunreinigungen.

PROVIDENCE, Rhode Island, 2. Oktober 2018 /PRNewswire/ -- EpiVax, Inc. („EpiVax") und CUBRC, Inc. („CUBRC") gaben heute bekannt, dass sie einen Zweijahresvertrag über 1 Million USD von der Food and Drug Administration (FDA) als Reaktion auf eine Broad Agency Announcement (BAA), FDA...

Le Bureau des médicaments génériques (OGD/FDA) attribue un contrat de la FDA de 1 million de dollars à CUBRC et EpiVax pour la démonstration et la validation de méthodes d'évaluation des risques d'immunogénicité pour les médicaments peptidiques génériques et leurs impuretés

PROVIDENCE, Rhode Island, 2 octobre 2018 /PRNewswire/ -- EpiVax, Inc. (« EpiVax ») et CUBRC, Inc. (« CUBRC ») ont annoncé aujourd'hui que la Food and Drug Administration (FDA) leur a accordé un contrat d'une durée de deux ans et d'un montant de 1 million USD en réponse à l'appel à...

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK and PROVIDENCE, R.I., June 12, 2018 /PRNewswire/ -- EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio...
Report incorrect company information

EpiVax Company Life and Culture

Report incorrect company information